Help employers find you! Check out all the
ORLANDO, Fla, Aug. 27, 2014 /PRNewswire/ -- TNI BioTech Inc. (OTCQB: TNIB), ("we" or the "Company") a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced it had received payment and will make its first shipments of Lodonal® to the Republic of Panama and The Republic of Malawi in conjunction with our marketing partner, The Brewer Group, Inc.
Commenting on the initial shipments, Noreen Griffin, CEO of TNI BioTech, stated, "Extensive work has been conducted and funds spent over the last twelve months obtaining local regulatory approval preparing for the launch of Lodonal® in these markets including participation at health conferences, drug dossiers, clinical case studies and training for sales professionals. We are confident that our distributors and sales teams are well positioned to establish Lodonal® as a major competitor in the treatment of cancer and autoimmune diseases in emerging nations. We are looking forward to launching Lodonal® in additional markets in the fourth quarter of 2014."
Lodonal® is an active immunotherapy with low dose naltrexone (LDN), an oral medication that works by activating a patient's immune system against HIV/AIDS and tumor cells or by rebalancing the immune system of patients with autoimmune diseases with no toxic side effects.
Lodonal® competes in the advanced cancer and autoimmune drug market. Global Industry Analysis, Inc. recently released a comprehensive global report on the Autoimmune Disease Therapeutics market, which stated that the global market for Autoimmune Disease Therapeutics is projected to exceed US$77 billion by the year 2017, driven by the rising incidence of autoimmune complications worldwide. We believe that Lodonal® has demonstrated potential clinical and economic advantages over existing treatments for a number of chronic and acute autoimmune diseases, such as HIV/AIDS, certain cancers, rheumatoid arthritis, multiple sclerosis, Crohn's Disease and inflammatory bowel disease.
TNIB previously announced the launch of Lodonal® sales through PanAm Global Logistics, Inc. in conjunction with The Brewer Group, Inc. to the Republic of Malawi, Africa. "We are very excited to work with PanAm to begin distributing Lodonal® in Africa," stated His Excellency Ambassador Jack Brewer, founder and CEO of The Brewer Group. "The Brewer Group strives to serve a global vision with a social focus through all our advisory work and this opportunity to spread awareness for Lodonal® in emerging markets exemplifies the power of our mission. We will immediately save lives by providing access to a trusted and affordable therapy to those living in the poorest areas in the world who are suffering from cancer and other autoimmune diseases."
In June 2014, TNIB announced the signing of a distribution agreement for the non-exclusive distribution of Lodonal® into Malawi, Panama, Sri Lanka, Egypt, Malaysia and Haiti. With this sale, TNIB, through it is wholly owned subsidiary Airmed Biopharma Limited, will begin monthly shipments under the existing agreement. TNIB anticipates revenue of $1,800,000 dollars over the next twelve months.
"We're very happy with the relationship that we've created with both PanAm Global Logistics, Inc and The Brewer Group, as this is an important step in implementing our international marketing and distribution program," said Noreen Griffin, CEO of TNI BioTech.
About TNI BioTech, Inc.
TNI BioTech is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin ("MENK") (sometimes referred to as opioid growth factor ("OGF")) and our Low Dose Naltrexone product ("LDN") or Lodonal, which have been shown to stimulate the immune system even in patients with advanced cancer.
Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
About Airmed Biopharma Limited
Airmed Biopharma Limited, a wholly owned Irish company, is the pharmaceutical sales division of TNI BioTech. Airmed is responsible for servicing sales orders for Lodonal® in countries where TNI BioTech has received sales approval.
About Cytocom, Inc.
Cytocom, Inc. is a biotechnology company that will initially focus on developing Low Dose Naltrexone (Lodonal®) and met-enkephalin in the investigation of unmet medical needs in the areas of oncological and inflammatory diseases.
About The Brewer Group, Inc.
Established in 2005, The Brewer Group is a multi-faceted global investment advisory firm focused on providing tailored services including capital markets, asset management, specialty finance and business development for public and private companies as well as high-profile clientele including athletes, entertainers and world leaders. TBG specializes in multiple sectors including: financial services; biotechnology & healthcare; sports; media & entertainment; wearable technology & consumer products; sustainable technology & agriculture; education & cultural exchange; and hospitality. The Brewer Group's relationships with high-profile clientele and affiliates including United Nations representatives, global organizations, distribution outlets, governments, key government and non-governmental officials, NPOs, agencies and unions as well as with various public and private corporations and international organizations place TBG in a unique position to execute a wide range of services around the globe. Additionally, The Brewer Group supports a 501(c)(3) non-profit organization, The Jack Brewer Foundation (JBF Worldwide), which uses its various programs and global initiatives to offer educational opportunities and economic development to underprivileged individuals around the world and its Chief Executive Officer, Jack Brewer, also serves as an Ambassador for Peace and Sport for the US Federation of Middle East Peace (USFMEP) at the United Nations. For further information, please visit www.thebrewergroup.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release and the statements of representatives and partners of the Company related thereto include various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" used in the Company's press releases and in the Company's filings with the Securities and Exchange Commission as well as Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve assumptions and significant risks and uncertainties. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release, and thus readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
For further information, please see http://www.tnibiotech.com
Contact: Dennis S. Dobson, 203-258-0159
SOURCE TNI BioTech, Inc.